BidaskClub cut shares of InVitae Corp (NASDAQ:NVTA) from a hold rating to a sell rating in a research note released on Thursday morning.

Several other research analysts have also recently commented on the company. Zacks Investment Research cut InVitae Corp from a strong-buy rating to a hold rating in a research report on Tuesday, October 17th. J P Morgan Chase & Co reissued an overweight rating and set a $15.00 price target (up from $14.00) on shares of InVitae Corp in a research report on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus price target of $13.50.

InVitae Corp (NASDAQ:NVTA) traded down $0.12 during trading on Thursday, hitting $8.31. 252,639 shares of the stock traded hands, compared to its average volume of 290,454. InVitae Corp has a 52-week low of $5.76 and a 52-week high of $11.88.

InVitae Corp (NASDAQ:NVTA) last posted its quarterly earnings data on Monday, November 6th. The medical research company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.37). InVitae Corp had a negative return on equity of 153.27% and a negative net margin of 199.20%.

TRADEMARK VIOLATION NOTICE: “BidaskClub Lowers InVitae Corp (NVTA) to Sell” was published by Watch List News and is the property of of Watch List News. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at

Hedge funds and other institutional investors have recently modified their holdings of the stock. Verity Asset Management Inc. increased its stake in shares of InVitae Corp by 0.8% during the second quarter. Verity Asset Management Inc. now owns 10,607 shares of the medical research company’s stock worth $101,000 after purchasing an additional 81 shares during the period. Lakeview Capital Partners LLC bought a new position in shares of InVitae Corp during the third quarter worth approximately $117,000. Donald L. Hagan LLC increased its stake in InVitae Corp by 30.0% during the 2nd quarter. Donald L. Hagan LLC now owns 13,000 shares of the medical research company’s stock worth $124,000 after acquiring an additional 3,000 shares during the period. Gabelli Funds LLC bought a new position in InVitae Corp during the 3rd quarter worth $131,000. Finally, State Board of Administration of Florida Retirement System bought a new position in InVitae Corp during the 3rd quarter worth $133,000.

About InVitae Corp

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.

Receive News & Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.